Natera Inc’s filing revealed that its Director ROWAN EMMA CHAPMAN acquired Company’s shares for reported $1.06 million on Dec 05 ’25. In the deal valued at $243.10 per share,4,366 shares were bought.
Then, Moshkevich Solomon sold 3,000 shares, generating $714,459 in total proceeds. Upon selling the shares at $238.15, the PRESIDENT, CLINICALDIAGNOSTICS now owns 109,061 shares.
Before that, Chapman Steven Leonard sold 4,400 shares. Natera Inc shares valued at $1,047,502 were divested by the CEO AND PRESIDENT at a price of $238.07 per share. As a result of the transaction, Chapman Steven Leonard now holds 140,416 shares, worth roughly $33.58 million.
A number of analysts have revised their coverage, including BNP Paribas Exane’s analysts, who increased its forecast for the stock in late October from “an Underperform” to “a Neutral”. RBC Capital Mkts started covering the stock on March 13, 2025. It rated NTRA as “an Outperform”.
Price Performance Review of NTRA
On Monday, Natera Inc [NASDAQ:NTRA] saw its stock fall -2.21% to $239.14. Over the last five days, the stock has gained 2.09%. Natera Inc shares have risen nearly 37.44% since the year began. Nevertheless, the stocks have risen 51.07% over the past one year. While a 52-week high of $245.59 was reached on 12/08/25, a 52-week low of $125.38 was recorded on 04/07/25.
Levels Of Support And Resistance For NTRA Stock
The 24-hour chart illustrates a support level at 235.83, which if violated will result in even more drops to 232.53. On the upside, there is a resistance level at 244.67. A further resistance level may holdings at 250.21.
How much short interest is there in Natera Inc?
A steep rise in short interest was recorded in Natera Inc stocks on 2025-11-14, dropping by -0.11 million shares to a total of 3.76 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 3.86 million shares. There was a decline of -2.86%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 23, 2025 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $200 price target.
